{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-059077","form_type":"8-K","ticker":"WHWK","cik":"0001422142","company_name":"Whitehawk Therapeutics, Inc.","filed_at":"2023-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.872237+00:00","generated_at":"2026-06-18T12:57:00.205418+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aadi Bioscience CEO Brendan Delaney resigns; CFO Scott Giacobello named interim CEO","bullets":["Brendan Delaney resigned as President, CEO, and director effective March 14, 2023, for personal reasons, not due to any disagreement.","CFO Scott Giacobello appointed Interim CEO and President effective March 15, 2023, while retaining CFO role.","Founder Neil Desai, Ph.D., continues as Executive Chairman and will assist with leadership transition.","Board has initiated a search for a permanent CEO; Giacobello's interim role ends when successor is appointed."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-059077","json":"https://secwatch.observer/filing/0001193125-23-059077.json","markdown":"https://secwatch.observer/filing/0001193125-23-059077.md","text":"https://secwatch.observer/filing/0001193125-23-059077.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422142/000119312523059077/0001193125-23-059077-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422142/000119312523059077/d377824d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T12:57:00.205418+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"77baff1399","claim":"Brendan Delaney resigned as President and Chief Executive Officer at Whitehawk Therapeutics, Inc..","evidence_excerpt":"On March 2, 2023, Brendan Delaney submitted a letter to the Board of Directors (the “Board”) of Aadi Bioscience, Inc. (the “Company”) resigning from his position as the Company’s President and Chief Executive Officer (“CEO”) and as a member of the Board of Directors, effective March 14, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422142/000119312523059077/0001193125-23-059077-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"a936aa9027","claim":"Scott Giacobello was appointed as Interim Chief Executive Officer and President at Whitehawk Therapeutics, Inc..","evidence_excerpt":"Effective March 15, 2023, the Board appointed Scott Giacobello, the Company’s Chief Financial Officer, to serve as the Company’s Interim CEO and President and principal executive officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422142/000119312523059077/0001193125-23-059077-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Executive Officer and President"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}